Navigation Links
Cobalis Expects to Report Phase III Top-Line Results in May

IRVINE, Calif.--(BUSINESS WIRE)--Apr 30, 2007 - Cobalis Corp. (OTC BB: CLSC), a pharmaceutical development company specializing in anti-allergy medications, today announced it has been informed by its independent contract research organization that it would need more time to combine Cobalis' three locked data bases into a single database before un-blinding and conducting the statistical analysis required to generate top-line results for Cobalis' twin pivotal Phase III Clinical Trials of PreHistin(TM) in seasonal allergic rhinitis. The Company anticipates reporting its top-line results later in May.

About Cobalis Corp.

Cobalis Corp. is a specialty pharmaceutical development company specializing in medications to prevent and treat atopic disease, including allergies, migraine headache, atopic asthma and dermatitis. Its flagship drug candidate PreHistin is an allergy medication in Phase III clinical development. Cobalis plans to seek FDA approval to market PreHistin over-the-counter in the US. For further information, visit www.cobalis.com

Safe Harbor

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cobalis disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to the timing, scope or expected outcome of the Company's clinical development of its drug candidates, the potential benefits of the Company's drug candidates and the size of the potential market for the Company's products. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and un certainties relating to securing funding for ongoing operations including clinical trials, difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product approval or market acceptance (including the risk that current and past results of clinical trials are not necessarily indicative of future results of clinical trials), the development of competing products by our competitors; uncertainties related to the Company's dependence on third parties and partners; and those risks described in our quarterly report on Form 10-QSB filed with the SEC on February 20, 2007.

Contact

Jaffoni & Collins Incorporated
David Collins or Steven Hecht, 212-835-8500
CLSC@jcir.com


'"/>




Related medicine technology :

1. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July ... UTHR ) announced today that it will report ... opens on Thursday, July 27, 2017. ... on Thursday, July 27, 2017, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based ... today announced the completion of a $12.7 million Series A ... as well as the participation of existing investors. ... the support of New Ventures III and our current investors, ... the potential of our platform technology to transform the course ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... MedMatchPlus+ has ... chances of acceptance to a residency in a United States hospital. Being accepted ... the U.S. , According to data released by the ECFMG®, every year, 50 ...
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon ... the signature product of her research center at Bio-Logic Aqua Research® Water Life ... and the greatest number of sufferers of blindness. “We think that Nature’s Tears® ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the ... from the Multicenter Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related ... though activity levels decline over time. The study, presented today at the ...
(Date:7/21/2017)... ONTARIO, CANADA (PRWEB) , ... July 21, 2017 ... ... give insight into why concussion rates are on the rise, say researchers presenting ... Meeting today in Toronto, Ontario, Canada. , “The combination of evaluating the patterns ...
(Date:7/20/2017)... ... 2017 , ... ChenMed , a leading provider of value-based care for ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family ... of Ambulatory Services for the UVA Health System, brings 30 years of highly relevant ...
Breaking Medicine News(10 mins):